Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants With DEE Followed by an Open-Label Extension
Conditions
Interventions
1.0mg/kg/day PRAX-562
1.5mg/kg/day PRAX-562
+1 more
Locations
5
United States
Praxis Research Site
La Jolla, California, United States
Praxis Research Site
Gulf Breeze, Florida, United States
Praxis Research Site
Chevy Chase, Maryland, United States
Praxis Research Site
Roseville, Minnesota, United States
Praxis Research Site
São Paulo, Brazil
Start Date
July 9, 2025
Primary Completion Date
July 1, 2026
Completion Date
July 1, 2027
Last Updated
December 18, 2025
Lead Sponsor
Praxis Precision Medicines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions